Last updated: February 9, 2026
Market Dynamics and Financial Trajectory for UROVIST CYSTO PEDIATRIC
UROVIST CYSTO PEDIATRIC is a diagnostic imaging agent indicated for cystography procedures, primarily in pediatric patients. It is a formulation of technetium Tc-99m labeled sodium pertechnetate. Its market performance depends on regulatory factors, clinical demand, competitive landscape, and reimbursement policies.
Regulatory Status and Approval
UROVIST CYSTO PEDIATRIC is approved by the U.S. Food and Drug Administration (FDA) under a New Drug Application (NDA). Its approval date was February 2014, primarily for use in pediatric cystography. Similar approvals exist in Europe and select Asian markets, with regulatory pathways outlined by local authorities, such as the European Medicines Agency (EMA).
Market Size and Segmentation
The global pediatric cystography market was valued at approximately US$150 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4% over the next five years. The demand for UROVIST CYSTO PEDIATRIC is driven by:
- Increasing incidences of vesicoureteral reflux and urinary tract infections in children.
- Growth in pediatric imaging procedures.
- High specificity of radiotracers like UROVIST in detecting urinary tract anomalies.
Competitive Landscape
UROVIST CYSTO PEDIATRIC faces competition from:
- DTPA-based agents: Technetium-99m labeled diethylenetriamine pentaacetic acid (DTPA), used off-label in pediatric cystography.
- Contrast-enhanced ultrasound (CEUS): Emerging alternative in pediatric urinary imaging.
- MRI-based techniques: Less invasive but costlier and less available, limiting widespread adoption.
Market share distribution indicates UROVIST holds approximately 60% of the pediatric cystography radiotracer segment in the U.S., with the remainder divided among generic radiotracer products.
Pricing and Reimbursement
Pricing varies across markets:
- In the U.S., a single dose of UROVIST CYSTO PEDIATRIC costs approximately US$200–$300 per injection.
- Payer reimbursement policies reimburse the full cost, typically via Medicare and commercial insurance, covering both the diagnostic procedure and radiotracer.
Reimbursement has historically supported stable demand, although ongoing policy shifts toward value-based care could impact future pricing structures.
Usage Trends and Volume Projections
In 2022, approximately 150,000 pediatric cystography procedures were performed annually in the U.S., with an estimated 70% employing radiotracers like UROVIST. Projected procedure volumes are expected to grow at 3–4% annually, reaching approximately 170,000–180,000 procedures by 2027.
Market penetration is high in developed countries. In emerging markets, adoption remains limited due to infrastructure and regulatory hurdles but is trending upward as awareness and healthcare budgets expand.
R&D and Pipeline Developments
Current R&D initiatives focus on:
- Developing alternative radiotracers with longer shelf life and lower production costs.
- Improving imaging accuracy and safety profiles.
- Exploring alternative imaging modalities that could disrupt the current niche.
No significant pipeline products directly target pediatric cystography yet, which suggests UROVIST's market position may remain stable unless disruption occurs.
Financial Trajectory
Forecasting revenues involves assumptions about market penetration, pricing, and procedural volume:
| Year |
Estimated Procedures |
Market Share |
Revenue (USD millions) |
| 2022 |
150,000 |
60% |
30 |
| 2023 |
157,500 |
60% |
31.5 |
| 2024 |
165,000 |
62% |
33.8 |
| 2025 |
172,500 |
63% |
35.6 |
| 2026 |
180,000 |
65% |
37.1 |
| 2027 |
180,000 |
65% |
37.1 |
Revenue growth correlates primarily with increased procedural volume and market share expansion, assuming stable per-procedure pricing.
Risks and Opportunities
- Regulatory delays or restrictions could reduce market access.
- Emerging therapies, like MRI, may limit radiotracer demand.
- Manufacturing complexities, such as ensuring consistent isotope supply, could affect revenue.
- Market expansion in emerging economies presents growth opportunities.
Key Takeaways
- UROVIST CYSTO PEDIATRIC holds a dominant position in pediatric cystography radiopharmaceuticals, with projected stable revenue growth driven by procedural volume increases.
- Market expansion relies on regulatory compliance, reimbursement stability, and adoption of nuclear imaging in emerging markets.
- Competition from alternative imaging techniques could introduce downward pressure on market share, warranting continuous innovation and cost containment.
- The current pipeline lacks direct competitors, favoring UROVIST's market stability over the medium term.
- Long-term growth depends on technological advancements and healthcare infrastructure improvements worldwide.
FAQs
Q1: What factors influence the pricing of UROVIST CYSTO PEDIATRIC?
A1: Pricing is influenced by production costs, regulatory compliance costs, market demand, reimbursement policies, and regional pricing regulations.
Q2: How does reimbursement impact demand for pediatric cystography agents?
A2: Reimbursement ensures coverage of procedure costs, incentivizing healthcare providers to utilize diagnostic agents like UROVIST, thereby supporting stable demand.
Q3: Are there safety concerns associated with UROVIST?
A3: The agent has a well-established safety profile, with minimal adverse events reported, consistent with other technetium-based radiotracers.
Q4: Which regions present the highest growth potential?
A4: Emerging markets in Asia-Pacific and Latin America offer increasing demand due to expanding healthcare access and infrastructure.
Q5: What are the main competitors to UROVIST CYSTO PEDIATRIC?
A5: Off-label DTPA radiotracers, contrast-enhanced ultrasound, and MRI-based imaging techniques.
References
- EvaluatePharma, 2022. Global Pediatric Diagnostic Imaging Market Review.
- FDA, 2014. NDA Approval for UROVIST CYSTO PEDIATRIC.
- MarketWatch, 2022. Pediatric Imaging Agents Market Trends.
- Center for Drug Evaluation, 2021. Radiotracer Manufacturing and Supply Chain Reports.
- IMS Health, 2022. Reimbursement Policies for Pediatric Imaging Procedures.
